ITHRA-DUBAI
27.4.2022 09:32:04 CEST | Business Wire | Press release
Ithra Dubai, a leading real estate developer and manager, fully owned by the Investment Corporation of Dubai, is pleased to announce the grand opening of the Dubai Gold Souk Extension (GSE). The opening ceremony was attended by key representatives from Ithra Dubai and Dubai Jewellery Group. An inaugural celebration with a golden line-up of entertainment, activations, and promotions will take place until May 8th , creating a festive atmosphere the whole family will enjoy.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220427005005/en/
The Dubai Gold Souk Extension will rejuvenate Dubai’s historic heart of commerce and reignite Dubai’s reputation as the City of Gold, delivering an elevated shopping and trading experience. The GSE will be the crowning jewel of the Deira Enrichment Project, a modern mixed-use community developed for residential living, business, commerce, and leisure and features a transportation hub that connects Deira to the heart of Dubai, and ensures superior accessibility to the project.
The Dubai Gold Souk Extension maintains the charm and cultural characteristics of the original souk but offers a more urban experience with shaded walkways, superior facilities including workshops and co-working spaces, covered parking, restaurants, a nearby waterfront promenade, and a range of hotels; catering to residents, entrepreneurs, and tourists from around the world.
Of the 295 shops, over 50 jewellery brands have opened during the soft launch and for the grand opening, more brands and specialty restaurants are setting up shop.
Mr. Issam Galadari, Director and CEO of Ithra Dubai said, “The Gold Souk Extension is a tribute to Dubai’s legacy of trade, and we are proud to be part of it. The historic significance of this area has been uplifted to provide an enriched experience while accommodating the increasing number of visitors. Located in Dubai’s original trading hub, it will be one of Dubai’s top cultural attractions and the world’s destination for jewellery, revitalising Dubai’s moniker: the City of Gold.”
In line with Dubai’s 2040 Urban Master Plan, this 1,181,025 ft2 development will transform the Emirate’s legacy into modern reality, supporting trade, tourism, and growth to secure a golden future.
About the Deira Enrichment Project and the Gold Souk Extension:
With a mix of residential, retail, and hospitality offerings, Deira Enrichment Project will rejuvenate Dubai’s historic heart of commerce while preserving its cultural characteristics.
Deira is the cornerstone of Dubai’s trading legacy; a place rich in culture, history, and tradition. From apartments overlooking The Creek to an extension of the Deira Souk, the development will uplift the rich tapestry woven by communities past and present.
Covering a GFA area of 1,181,025 ft2 , the new Gold Souk Extension will host 295+ retail units, 255,000 ft2 of office space, and 468 high-quality residences.
*Source: AETOSWire
View source version on businesswire.com: https://www.businesswire.com/news/home/20220427005005/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release
The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav
New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release
Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom